Alaunos Therapeutics (TCRT)
Preclinical developer of ALN1003, an oral small molecule for obesity.
Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies
ALN1003 demonstrated consistent, favorable effects across key drivers of metabolic disease, including reductions in body weight and fat mass, improved insulin sensitivity, enhanced adipose function, and improved liver health in diet-induced obese mice A non-confidential investor presentation summarizing the preclinical dataset is now available FORT LAUDERDALE, Fla., May 26, 2026 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq: TCRT) today reported an integrated preclinical readout for ALN1003, the Company's investigational oral, non-hormonal, non-incretin small-molecule candidate for obesity and related metabolic disorders.
Weight Loss Data From Obese Mice Looks Promising For Alaunos Therapeutics, But Shares Drop
Alaunos Therapeutics Inc. (NASDAQ: TCRT) shares are down on Monday after the company announced preclinical proof-of-concept data for its lead drug candidate, ALN1003.
Short Interest in Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Drops By 14.6%
Alaunos Therapeutics, Inc. (NASDAQ: TCRT - Get Free Report) saw a significant decline in short interest in January. As of January 30th, there was short interest totaling 44,597 shares, a decline of 14.6% from the January 15th total of 52,250 shares. Based on an average daily trading volume, of 15,766 shares, the short-interest ratio is currently
Alaunos Therapeutics (NASDAQ:TCRT) Trading 3.1% Higher – What’s Next?
Alaunos Therapeutics, Inc. (NASDAQ: TCRT - Get Free Report) was up 3.1% during mid-day trading on Wednesday. The company traded as high as $3.00 and last traded at $3.00. Approximately 16,982 shares changed hands during mid-day trading, a decline of 48% from the average daily volume of 32,426 shares. The stock had previously closed at
Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering
HOUSTON, June 23, 2025 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Nasdaq: TCRT) (the “Company”) today announced that it has entered into a definitive agreement with certain investors (the “SPA”) for the purchase and sale of an aggregate of 610,399 shares of common stock (or pre-funded warrants in lieu thereof) at a purchase price of $3.36 per share (or pre-funded warrant in lieu thereof) in a registered direct offering (the “Offering”) on June 20, 2025 based on the 5-day average Nasdaq official closing price. The aggregate gross proceeds to the Company of this offering are expected to be approximately $2.0 million, before deducting the offering expenses payable by the Company.
PMGC Capital LLC Urges Alaunos Therapeutics (NASDAQ: TCRT) to Accept Term Sheet from Leading Wall Street Bank Behind Many Leading Crypto Strategies
NEWPORT BEACH, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- PMGC Capital LLC (“PMGC Capital”), a wholly owned subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB), today issued a public statement urging Alaunos Therapeutics, Inc. (NASDAQ: TCRT) to accept and act upon the term sheet previously facilitated through a leading Wall Street Bank.
Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today?
Alaunos Therapeutics (NASDAQ: TCRT ) stock is up on Monday despite a lack of news from the clinical-stage oncology-focused cell therapy company. There are no new press releases or filings with the Securities and Exchange Commission (SEC) that explain why the stock is up today.
Why Is Alaunos Therapeutics (TCRT) Stock Up 14% Today?
Alaunos Therapeutics (NASDAQ: TCRT ) stock is heading higher on Tuesday following the release of the clinical-stage oncology-focused cell therapy company's Q3 earnings report. The Alaunos Therapeutics earnings report starts with earnings per share of -4 cents.
Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives
HOUSTON, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced financial results for the third quarter ended September 30, 2023. As previously announced, the Company is exploring strategic alternatives with Cantor Fitzgerald & Co. as its strategic advisor. Alaunos continues to reduce spend and cost-savings measures taken to date are expected to extend its cash runway into the second quarter of 2024.
Alaunos (TCRT) to Wind Down Sole Clinical Study, Stock Dips 65%
Due to a lack of funding needs, Alaunos (TCRT) decides to end its only clinical study. The company will instead focus on its hunTR TCR discovery platform and explore broad strategic alternatives.
Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives
HOUSTON, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced financial results for the second quarter ended June 30, 2023. The Company also announced a strategic reprioritization to focus on its hunTR ® TCR discovery platform, wind down its TCR-T Phase 1/2 Library trial and explore broad strategic alternatives for the Company. Alaunos is implementing a cost-savings plan that includes a reduction in workforce by approximately 60%.
Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023
HOUSTON, May 03, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that it will report financial results for the first quarter ended March 31, 2023, on Wednesday, May 10, 2023, before the open of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 9:00 a.m. ET to review the financial results and provide a corporate update.
Alaunos Therapeutics to Participate in Upcoming Investor Conferences in April
HOUSTON, March 29, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a leading T-cell receptor (TCR) cell therapy company advancing a clinical-stage pipeline of therapeutics for solid tumors, today announced that company management will be participating in the following upcoming investor conferences.
Alaunos Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 7, 2023
HOUSTON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2022, on Tuesday, March 7, 2023, before the open of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:30 a.m. ET to review the financial results and provide a corporate update.
Is Alaunos Therapeutics (TCRT) Outperforming Other Medical Stocks This Year?
Here is how Alaunos (TCRT) and Autolus Therapeutics PLC Sponsored ADR (AUTL) have performed compared to their sector so far this year.
After Plunging 42% in 4 Weeks, Here's Why the Trend Might Reverse for Ziopharm (TCRT)
Ziopharm (TCRT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Alaunos Therapeutics Still Waiting For Home Run
First-in-human data from two patients using TCR-T cell therapy produced, at best, one partial response. While not targeting solid tumors, approved CAR-T cell therapies do demonstrate high complete response rates.
Alaunos Therapeutics, Inc. (TCRT) Q3 2022 Earnings Call Transcript
Alaunos Therapeutics, Inc. (NASDAQ:TCRT ) Q3 2022 Earnings Conference Call November 14, 2022 8:30 AM ET Company Participants Alex Lobo - Stern Investor Relations Kevin Boyle Senior - Chief Executive Officer Abhi Srivastava - Vice President, Technical Operations Drew Deniger - Vice President, Research and Development Mike Wong - Vice President, Finance Conference Call Participants Prakhar Agrawal - Cantor Fitzgerald James Shin - Wells Fargo Yale Jen - Laidlaw Thomas Flaten - Lake Street Capital Markets Operator Good day and thank you for standing by. Welcome to the Alaunos Therapeutics Third Quarter 2022 Financial Results Conference Call.
Alaunos Therapeutics to Present Data Highlighting its hunTR™ TCR Discovery Platform at the Society for Immunotherapy of Cancer 2022 Annual Meeting
HOUSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company today announced a poster presentation highlighting the potential of the Company's human neoantigen T-cell receptor platform (hunTR) to expand its TCR Library. The data will be presented at the Society for Immunotherapy of Cancer's (SITC) 37th Annual Meeting in Boston, Massachusetts from November 8-12, 2022.
Hot Penny Stocks To Watch As The Stock Market Crash Continues
Hot penny stocks to add to your watch list this week. Is it time to buy?